Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s approval – DEER PARK, Ill., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, ...

During the preclinical stage, the focus of forecasting is not necessarily on the product itself, but on the broader opportunity within the disease area. At this point, there is limited information ...

Apellis Pharmaceuticals reports $709 million in 2024 U.S. net product revenues, anticipates new drug submissions and organizational changes. Apellis Pharmaceuticals announced preliminary U.S. net ...

Journavx is one of three recently approved drugs in Vertex Pharmaceuticals' product lineup ... it's only about as powerful as Vicodin tablets. In a clinical trial with patients who received ...

FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals ... Track designation to NPI-001 (N-acetylcysteine amide) tablets, Nacuity’s proprietary investigational therapy ...

This analysis examines Incyte's current position, growth strategies, and the challenges it faces in the evolving pharmaceutical ... guidance for Jakafi, the company's flagship product, to between ...

--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate ...

Incyte (NASDAQ:INCY) Corporation (NASDAQ:INCY), with a market capitalization of $13.9 billion, finds itself at a critical juncture as it faces the looming expiration of patents for its flagship ...